Fintel reports that on August 9, 2023, Morgan Stanley maintained coverage of Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 229.14% Upside
As of August 2, 2023, the average one-year price target for Sage Therapeutics is 62.50. The forecasts range from a low of 37.37 to a high of $110.25. The average price target represents an increase of 229.14% from its latest reported closing price of 18.99.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sage Therapeutics is 118MM, an increase of 1,039.90%. The projected annual non-GAAP EPS is -8.46.
What is the Fund Sentiment?
There are 494 funds or institutions reporting positions in Sage Therapeutics. This is an increase of 22 owner(s) or 4.66% in the last quarter. Average portfolio weight of all funds dedicated to SAGE is 0.19%, an increase of 9.75%. Total shares owned by institutions increased in the last three months by 2.55% to 59,004K shares. 
The put/call ratio of SAGE is 0.69, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 5,714K shares representing 9.54% ownership of the company. In it's prior filing, the firm reported owning 5,516K shares, representing an increase of 3.47%. The firm increased its portfolio allocation in SAGE by 12.64% over the last quarter.
Bellevue Group holds 3,090K shares representing 5.16% ownership of the company. In it's prior filing, the firm reported owning 2,969K shares, representing an increase of 3.91%. The firm increased its portfolio allocation in SAGE by 25.18% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 2,398K shares representing 4.01% ownership of the company. In it's prior filing, the firm reported owning 1,874K shares, representing an increase of 21.88%. The firm increased its portfolio allocation in SAGE by 35.32% over the last quarter.
Price T Rowe Associates holds 1,908K shares representing 3.19% ownership of the company. In it's prior filing, the firm reported owning 1,897K shares, representing an increase of 0.58%. The firm increased its portfolio allocation in SAGE by 2.98% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,581K shares representing 2.64% ownership of the company. In it's prior filing, the firm reported owning 1,552K shares, representing an increase of 1.82%. The firm increased its portfolio allocation in SAGE by 3.46% over the last quarter.
Sage Therapeutics Background Information
(This description is provided by the company.)
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing new pathways with the goal of improving brain health, and its depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Its mission is to make medicines that matter so people can get better, sooner.
Additional reading:
- 2014 Employee Stock Purchase Plan, as amended
- Supply Agreement by and between the Registrant and CyDex Pharmaceuticals, Inc., dated December 13, 2012, as amended August 21, 2013 and April 30, 2014
- Amendment No. 3 to Supply Agreement, by and between the Registrant and CyDex Pharmaceuticals, Inc., dated September 25, 2015
- Commercial License Agreement by and between the Registrant and CyDex Pharmaceuticals, Inc., dated August 21, 2013, as amended April 30, 2014
- Non-Exclusive License Agreement by and between the Registrant and the Regents of University of California, dated October 23, 2013, as amended May 14, 2014
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
